Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112736 | 1.00 | SIGMAR1 (0.68) | SIGMAR1POLBBCHEIDO1THRB | |
| SCHEMBL20525543 | 0.89 | SIGMAR1 (0.52) | SIGMAR1BCHEKDM4ESMN1; SMN2 | |
| SCHEMBL3413593 | 0.82 | SIGMAR1 (0.65) | SIGMAR1POLBIDO1THRBTAAR1 | |
| SCHEMBL11235861 | 0.82 | SMN1; SMN2 (0.51) | SIGMAR1POLBTHRBLMNATAAR1 | |
| N-Benzylamphetamine SCHEMBL2798189 | 0.81 | SIGMAR1 (1.00) | SIGMAR1POLBLMNATAAR1SLC18A2 | |
| N-Benzylamphetamine SCHEMBL2451256 | 0.81 | SIGMAR1 (1.00) | SIGMAR1POLBLMNATAAR1SLC18A2 | |
| N-Benzylamphetamine SCHEMBL2795222 | 0.81 | SIGMAR1 (1.00) | SIGMAR1POLBLMNATAAR1SLC18A2 | |
| SCHEMBL172633 | 0.81 | SIGMAR1 (0.70) | SIGMAR1POLBBCHELMNATAAR1 | |
| SCHEMBL13675825 | 0.81 | SIGMAR1 (0.70) | SIGMAR1POLBBCHELMNATAAR1 | |
| SCHEMBL172363 | 0.81 | SIGMAR1 (0.70) | SIGMAR1POLBBCHELMNATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| EP-4359081-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | Novartis AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| CN-117425649-A | Pyrazole derivatives as KRAS mutein inhibitors | 诺华股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2022269508-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022269508-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | KRAS, NRAS, APC | SIGMAR1 4411/4885POLB 2501/4885BCHE 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.